Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06312722
Status:
RECRUITING
Last Update Posted:
2024-03-15
First Post:
2024-03-08
Brief Title:
Safety and Effectiveness of the Optilume BPH Catheter System in a Post-Market Study
Sponsor:
Urotronic Inc
Organization:
Urotronic Inc
Study Overview
Official Title:
Safety and Effectiveness of the Optilume BPH Catheter System in a Post-Market Study
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PEAK
Brief Summary:
The goal of this clinical trial is to verify the continued safety and effectiveness for the Optilume BPH Catheter System
Detailed Description:
The goal of this clinical trial is to verify the continued safety and effectiveness for the Optilume BPH Catheter System
STUDY ENDPOINTS
Primary Efficacy Endpoint
The primary efficacy endpoint is the average IPSS improvement from baseline to 12 months
Primary Safety Endpoint
The primary safety endpoint is the freedom from composite treatment-related adverse SAEs
Key Secondary Safety Endpoint Semen Sub-Study Only
The average change from baseline in sperm concentration at 13 weeks 3 months post-procedure will be compared against a performance goal of -30 30 decrease from baseline
Ancillary Endpoints
Ancillary Safety Endpoint
1 Frequency and severity of treatment-related AEs Adverse events will be collected and assessed for relatedness to the device and the procedure as well as for severity The Clavien-Dindo severity grading scale is a commonly used criteria in the urology community An independent medical monitor will adjudicate all treatment-related events
2 Frequency and severity of all AEs All adverse events will be summarized and reported regardless of relatedness to the device or procedure
3 Change from baseline in semen characteristics over time semen sub-study only Semen characteristics concentration count motility will be summarized at each follow-up including change from baseline values Reported values for each subject will represent an average of 2 samples collected at each timepoint Summary statistics will be based on reported values for each subject at each timepoint
4 Proportion of subjects experiencing 50 decrease in sperm concentration from baseline The proportion of subjects experiencing 50 decrease in sperm concentration from baseline to 3 6 and 12 months will be reported
Ancillary Efficacy Endpoints
5 Improvement in IPSS over time The IPSS tool is the most commonly reported symptom score for obstructive urinary symptoms secondary to BPH Average IPSS scores absolute change from baseline and percent change from baseline will be reported at each follow-up timepoint
6 Improvement in ICS male SF over time The International Continence Society ICS male short form SF has three domains to assess urinary symptoms voiding symptoms eg hesitancy incomplete voiding etc storage symptoms eg frequency and leakage symptoms Average total scores and average scores for each domain along with changes from baseline will be reported at each follow-up timepoint
7 Improvement in Qmax over time Uroflowmetry represents an objective measure of relief of obstruction Average peak urinary flow rate Qmax and change from baseline will be reported at each follow-up timepoint
8 Improvement in PVR over time Residual urine in the bladder due to incomplete emptying is an important clinical consideration in subjects with obstructive BPH Average PVR and change from baseline will be reported at each follow-up timepoint
9 Freedom from repeat intervention time-to-event The proportion of subjects free from repeat surgical or endoscopic intervention for BPH will be reported over time utilizing the Kaplan-Meier method
STUDY ENDPOINTS
Primary Efficacy Endpoint
The primary efficacy endpoint is the average IPSS improvement from baseline to 12 months
Primary Safety Endpoint
The primary safety endpoint is the freedom from composite treatment-related adverse SAEs
Key Secondary Safety Endpoint Semen Sub-Study Only
The average change from baseline in sperm concentration at 13 weeks 3 months post-procedure will be compared against a performance goal of -30 30 decrease from baseline
Ancillary Endpoints
Ancillary Safety Endpoint
1 Frequency and severity of treatment-related AEs Adverse events will be collected and assessed for relatedness to the device and the procedure as well as for severity The Clavien-Dindo severity grading scale is a commonly used criteria in the urology community An independent medical monitor will adjudicate all treatment-related events
2 Frequency and severity of all AEs All adverse events will be summarized and reported regardless of relatedness to the device or procedure
3 Change from baseline in semen characteristics over time semen sub-study only Semen characteristics concentration count motility will be summarized at each follow-up including change from baseline values Reported values for each subject will represent an average of 2 samples collected at each timepoint Summary statistics will be based on reported values for each subject at each timepoint
4 Proportion of subjects experiencing 50 decrease in sperm concentration from baseline The proportion of subjects experiencing 50 decrease in sperm concentration from baseline to 3 6 and 12 months will be reported
Ancillary Efficacy Endpoints
5 Improvement in IPSS over time The IPSS tool is the most commonly reported symptom score for obstructive urinary symptoms secondary to BPH Average IPSS scores absolute change from baseline and percent change from baseline will be reported at each follow-up timepoint
6 Improvement in ICS male SF over time The International Continence Society ICS male short form SF has three domains to assess urinary symptoms voiding symptoms eg hesitancy incomplete voiding etc storage symptoms eg frequency and leakage symptoms Average total scores and average scores for each domain along with changes from baseline will be reported at each follow-up timepoint
7 Improvement in Qmax over time Uroflowmetry represents an objective measure of relief of obstruction Average peak urinary flow rate Qmax and change from baseline will be reported at each follow-up timepoint
8 Improvement in PVR over time Residual urine in the bladder due to incomplete emptying is an important clinical consideration in subjects with obstructive BPH Average PVR and change from baseline will be reported at each follow-up timepoint
9 Freedom from repeat intervention time-to-event The proportion of subjects free from repeat surgical or endoscopic intervention for BPH will be reported over time utilizing the Kaplan-Meier method
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None